Loading organizations...
Based in Cincinnati, Ohio, Blue Bridge is an AI-native system integrator and talent services firm that develops modular artificial intelligence agents to automate enterprise workflows. The organization serves Fortune 1000 companies by deploying AI assistants that optimize system integrations and augment human decision-making, utilizing an output-based pricing model rather than relying on traditional billable hours. The company's specialized talent division supports a network of over 100,000 candidates across engineering and IT, driving projected revenues of more than $10 million for 2025 following a 300% year-over-year growth rate. Operating with an AI division of 11 to 50 employees led by executives including Sylvia Helm and Kris Jones, the firm secured a $5 million investment in August 2025 to fund headcount expansion. The organization's dedicated artificial intelligence division was founded in 2024 by Mani Roy and Frank Morris.
Blue Bridge has raised $2.0M across 1 funding round.
Blue Bridge has raised $2.0M in total across 1 funding round.
Blue Bridge has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $2M Seed | — | EFounders, Idinvest Partners, Partech Ventures, Alexandre Dalyac, Didier Valet | Announced |
BlueBridge Technologies is a digital health technology company specializing in software and systems for connected medical devices, digital therapeutics, diagnostics, and patient-to-cloud platforms, primarily serving medtech, biopharma, and healthcare providers to manage chronic conditions like cancer, diabetes, Parkinson's, respiratory, and heart disease.[4][2][3] Its solutions streamline clinical trials, patient digitization, disease progression assessment using patient data, and integration with healthcare systems, enabling better outcomes for patients and providers.[3][1][4] Note: Search results identify two distinct entities—"BlueBridge Technologies" (Ireland-based, founded 2006, acquired by Everfield in 2022) focused on medtech innovation, and "Blue Bridge Technologies" (Latvia-based, founded 2007) offering practice management like SmartMedical for 370+ Latvian institutions; this overview centers on the more prominent Irish firm given query phrasing and result depth, with Latvian distinctions noted where relevant.[1][2][4]
BlueBridge Technologies was founded in 2006 in Dublin, Ireland, by a team of multi-skilled specialists in software, hardware, data science, cybersecurity, regulatory affairs, and quality, drawing from Silicon Valley tech, regulated finance, and manufacturing backgrounds.[2][4] The company emerged to address the need for intelligent components in connected medical-device ecosystems, anticipating that modern devices would require "brains" for managing chronic diseases.[4] Key milestones include developing the Respr device for Covid-19 monitoring with satellite data integration (supported by European Space Agency), participation in MDIC for SaMD threat modeling best practices, and acquisition by Everfield (financial acquisition, alive stage).[2][4] This evolution positioned it as a leader in digital health for life sciences, expanding from device software to end-to-end patient-to-cloud platforms.[3]
BlueBridge rides the wave of digital health transformation, particularly connected medical devices and patient-centric digitization amid rising chronic disease prevalence and demand for remote monitoring post-Covid.[2][4][3] Timing aligns with regulatory pushes for SaMD security, AI-driven diagnostics, and cloud integration in medtech/biopharma, amplified by initiatives like ESA collaborations and MDIC standards.[2][4] Market forces favoring it include aging populations, telemedicine growth, and biopharma's need for efficient clinical trials, positioning BlueBridge to influence ecosystems by enabling data-driven devices that improve outcomes and reduce workloads—e.g., via tools like Respr for real-time pandemic tracking.[2][1][3] Its Everfield backing expands global reach, accelerating adoption in life sciences.[2]
BlueBridge is poised for expansion in AI-enhanced digital therapeutics and secure connected devices, leveraging R&D investments and multidisciplinary expertise to capture medtech/biopharma demand amid trends like personalized medicine and cybersecurity mandates.[3][4] Expect deeper integration with wearables/IoT for chronic care, potential new ESA/pharma partnerships, and scaled patient-to-cloud platforms post-Everfield acquisition, evolving its influence from innovator to ecosystem enabler in a $500B+ digital health market.[2][3] As healthcare digitizes further, BlueBridge's regulated agility will drive pivotal impact, streamlining operations from patient intake to insurer settlements much like its Latvian tools already do at scale.[1][4]
Blue Bridge has raised $2.0M in total across 1 funding round.
Blue Bridge's investors include eFounders, IDInvest Partners, Partech Ventures, Alexandre Dalyac, Didier Valet.
